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Background: HCV is causing hundreds of cases yearly in Pakistan and has become a threat for Pakistani population.
HCV E2 protein is a transmembrane protein involved in viral attachment and thus can serve as an important target
for vaccine development but because of its variability, vaccine development against it has become a challenge.
Therefore, this study was designed to isolate the HCV E2 gene from Pakistani HCV infected patients of 3a genotype,
to perform In-silico analysis of HCV E2 isolated in Pakistan and to analyze HCV E2 protein sequence in comparison
with other E2 proteins belonging to 3a and 1a genotypes to find potential conserved B-cells and T-cell epitopes
that can be important in designing novel inhibitory compounds and peptide vaccine against genotype 3a and 1a.
Patients and methods: Patients were selected on the basis of elevated serum ALT and AST levels at least for six
months, histological examination, and detection of serum HCV RNA anti-HCV antibodies (3rd generation ELISA). RNA
isolation, cDNA synthesis, amplification, cloning and sequencing was performed from 4 patient’s serum samples in
order to get the HCV E2 sequence. HCV E2 protein of Pakistani origin was analyzed using various bioinformatics
tools including sequence and structure tools.
Results: HCV E1 protein modeling was performed with I-TASSER online server and quality of the model was
assessed with ramchandran plot and Z-score. A total of 3 B-cell and 3 T-cell epitopes were found to be highly
conserved among HCV 3a and 1a genotype.
Conclusion: The present study revealed potential conserved B-cell and T-cell epitopes of the HCV E2 protein along
with 3D protein modeling. These conserved B-cell and T-cell epitopes can be helpful in developing effective
vaccines against HCV and thus limiting threats of HCV infection in Pakistan.
Keywords: HCV, E2 protein, Sequencing, 3D structure, EpitopesIntroduction
Hepatitis C virus (HCV) is a global health problem and
a significant risk factor in developing liver associated
diseases including hepatocellular carcinoma. HCV has
affected 270 million people worldwide of which 10 mil-
lion belongs to Pakistan [1]. Hundreds of HCV cases are
reported each year in Pakistan and according to the
prevalence analysis it is clear that HCV genotype 3a is
most common in all provinces of Pakistan [2] except in
Balochistan where the most prevalent subtype is 1a [3].* Correspondence: usmancemb@gmail.com
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reproduction in any medium, provided the orDue to six genotypes and their variability, HCV vaccine
development has always been a challenge and for this,
structural and non- structural proteins are being
targeted to develop an effective vaccine.
HCV is a plus strand virus having a genomic RNA and
viral envelope proteins, namely E1 and E2 [4] that are
anchored in a host derived lipid protein membrane sur-
rounding the nucleocapsid composed of several copies
of core protein. E1 and E2 have molecular weights of
33–35 and 70–72 kDa, respectively [5-7]. E2 is highly
glycosylated and contains up to 11 N-linked glycosylation
sites, with most of the sites being well conserved. Intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sequences differing up to 80% between HCV genotypes and
between subtypes of the same genotype [8-10]. E2 glyco-
protein is a key molecule regulating the interaction of the
HCV with cell surface proteins and binds to the major
extracellular loop of human CD81, a tetraspanin expressed
in various cell types including hepatocytes and B lympho-
cytes [11], its truncated forms also interacts with scavenger
receptor type B class 1 protein (SRB-1) and high density
lipoprotein (HDL) binding molecule [12-15]. Mannose
binding proteins (DC-SIGN and L-SIGN) have been sug-
gested to have interactions with the HCV E2 but their
function in viral entry is unclear [16]. HCV E2 posses’
glyco-sylation sites which interact directly with cell surface
receptors enabling the virus to enter the cell [17-20], there-
fore it is important to target this protein to stop viral entry.
For designing effective inhibitors against envelope
proteins, it is important to have knowledge of se-
quence and structure of protein. Bioinformatics ana-
lysis has open new vistas to provide more insights
into protein sequence and structural features. There-
fore, this study was designed to isolate the HCV E2
sequence from HCV infected patients of 3a genotype
and to analyze conservation and variability for design-
ing conserved B-cells and T-cells epitopes. B-cell and
T-cell epitopes are important in raising the desired
immune responses and number of epitopes and
modulation of immune recognition of antigens can be
influenced by deglycosylation of viral glycoproteins
[21]. As knowledge of epitopic regions on protein is
important in designing effective inhibitors, [22] there-
fore, both B-cell and T-cell epitopes were predicted
that were well conserved in the HCV E2 protein of
genotype 3a and 1a.Methodology
Source of serum samples
The local HCV 3a serum samples from 4 patients were col-
lected from CAMB (Center for Applied Molecular Biology)
diagnostic laboratory, Lahore, Pakistan after clinical diagno-
sis under the provision of the Institutional Review Board
(IRB) of NCEMB (National Center of Excellence in Mo-
lecular Biology), University of the Punjab Lahore, Pakistan.
The participating subjects gave informed consent for the
collection of blood samples for this study. Patients were se-
lected on the basis of elevated serum ALT and AST levelsTable 1 Sequences of Primer used for PCR amplification of th
No. Primer name Sequences 5΄-3΄
1 E2-F CGCAATCATCATGGTTATG
2 E2-R CCAAGGCTGCTTCTGTCTGat least for six months, histological examination, and detec-
tion of serum HCV RNA anti-HCV antibodies (3rd gener-
ation ELISA).RNA isolation, cDNA synthesis, amplification and cloning
of the HCV E2 gene
All the steps of RNA isolation from serum samples were
carried out in the type IIB Biosafety hood (Beckman
Coulter, USA). RNA from collected serum samples was
extracted using a Purescript® RNA Isolation kit (Gentra
System Pennsylvania, USA) according to the manufacturer’s
protocol. Extracted RNA was reverse transcribed into com-
plementary DNA (cDNA) using Moloney murine leukemia
virus reverse transcriptase (MMLV-RTase) (Fermentas,
USA). A set of primers was designed for PCR amplification
of the HCV E2 gene from cDNA of HCV 3a infected
patients, against HCV isolate NZL1 (D17763) sequence
retrieved from NCBI (National Center for Biotechnology
Information) using Primer3 software (http://frodo.wi.mit.
edu/) (Table 1). To efficiently produce the desired PCR
products, the amplification was performed with 4 μl of
cDNA using forward and reverse primers in a thermal
cycler with Taq DNA polymerase. PCR protocol was
used that involved 35 cycling steps at 54°C annealing
temperature. After the completion of PCR reactions,
DNA was resolved on 1.2% TAE agarose gel along with
100 bp DNA size marker on the basis of molecular
weight; mixing samples with 6x loading dye (Fermentas,
USA). Then gel was observed under the ultra violet (U.V)
light. Purification of DNA from the agarose gel slice was
done with QIA quick gel extraction kit (Qiagen, USA). In-
dividual PCR products were inserted into TA cloning vec-
tor, pCR2.1-TOPO (Invitrogen, USA). To confirm the HCV
E2 insert in pCR2.1 vector, regular PCR was run as de-
scribed above using gene specific primers and plasmid
DNA as template. Moreover, restriction digestion of the
pCR2.1 vector was done by endonuclease EcoR1 restriction
enzyme and incubated at 37°C for one hour with reaction
mixture. All plasmid constructs were sequenced for con-
firmation of the insert at the standard cycling conditions.
Sequence analysis of the plasmid DNA was performed
according to the manufacturer’s protocol using BigDye™
Terminator v3.0 Cycle sequencing kit (Applied Biosystems,
Germany). Sequencing for both positive and negative
strands on an automated sequencer (Applied Biosystems
3700 DNA Analyzer, Germany) was performed. Three fulle HCV E2 gene
Primer size PCR product size
TTCTCA 25 1151 bp
TGATA 24
Figure 2 Confirmation of expression vector via restriction
digestion. Restriction digestion of pCR2.1/E2 vector, sample #1-10
are digested (gene of 1151 bp) and undigested plasmid respectively.
1 Kb DNA Size Marker (M1) and λ/HindIII DNA size Marker (M2)
are shown.
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were submitted in the NCBI database having accession
no. GQ355940, GQ355941 and GQ355942.
Sequence analysis, homology modeling and
stereochemical analysis
HCV E2 sequence of 3a genotype (GQ355940.1) was
used to develop three-dimensional structure of E2 pro-
tein through homology modeling because crystal or
NMR structure of the HCV E2 protein was not available
in Protein Data Bank (PDB) (http://www.rcsb.org/pdb/home/
home.do). Different parameters of primary structure analysis
were computed using ProtParam online tool [23]. The sec-
ondary structure of the protein was computed using different
servers. DiANNA tool [24] was used to check the system
classification and disulfide connectivity. This knowledge can
be helpful in understanding the secondary structure of the
protein since disulfide bond bridges are important in protein
fold stabilization. The 3D model was generated using the
I-TASSER online server [25] which generates 3D models
along with their confidence score (C-Score). After generating
3D model, structure analysis and stereochemical analysis
were performed using different evaluation and validation
tools. The Psi/Phi Ramachandran plot was obtained using
PROCHECK [26] which helped in evaluating backbone con-
formation. Ramachandran plot was also used to check non-
GLY residues at the disallowed regions. Quality of the model
was assured using Z - scores, which is indicative of overall
model quality and to assure that the predicted structure is
within range of score as found in native proteins. PROSA
web tool [27] was used to determine Z-scores. Furthermore,
the generated model was submitted in the Protein model
database (PMDB) (http://mi.caspur.it/PMDB/main.php) hav-
ing PMDB identifier PM0078776.
T-cell epitope and B-cell epitope prediction
Transmembrane topology of the E2 protein was checked
using TMHMM online tool [28] and antigenicity ofFigure 1 HCV E2 gene amplification through PCR. PCR
amplification of E2 gene of HCV 3a genotype from different patients’
serum samples. Sample # 2, 3, 6, and 7 shows amplified PCR product
of 1151 bp of E2. 100 bp DNA size Marker (M) and negative PCR (−ve)
are shown. 1–7 samples are from different patients.protein was checked using Vexigen v2.0 online antigen
prediction server [29]. T-cell epitopes were predicted
using Epijen v1.0 [30] online server using HLA Alleles
A*0101, A*0201, A*0202, A*0203, A*0206, A*0301,
A*1101, B*07, B*51. Proteasome cutoff was set to a
value of 0.1. TAP prediction cutoff was set to 5 and
output cut off threshold was set to a 5%. Transmem-
brane localization of epitopes with minimum IC50
value was checked and epitopes that were present in
transmembrane/exo-membrane region were selected
and checked for potential antigen or not. Only epitopes
that were in transmembrane/Exo-membrane region
and have a potential antigenicity score were subjected
to conservancy analysis. Furthermore, B-cell epitopes
were predicted using BCPred [31] online server with
75% specificity criteria for epitope prediction. Epitopes
exposed on the surface of the membrane were checked
for their antigenecity using Vexijen v2. 0 online server.
Both T-cell and B-cell epitopes were analyzed for their
conservancy among all retrieved sequences of E2 belong-
ing to genotype 3a and 1a. For this purpose, the IEDB
Epitope conservancy analysis server [32] was utilized.Conservation of epitopes
The degree of conservation of amino acid depicts there
structural and functional importance. For predicting ef-
fective and conserved peptides, E2 protein sequences be-
longing to HCV 3a and 1a genotype were retrieved from
the NCBI protein database (Additional file 1) and were
compared with the E2 sequence of Pakistan. Conserva-
tion and variation analysis of the HCV E2 was carried
out through the IEDB conservancy analysis tool. As the
HCV E2 protein is important in viral entry and highly
variable, therefore it is important to identify conserved
epitopes that can serve as best targets for potential in-
hibitors and vaccine.
Figure 3 Secondary structure of HCV E2 of Pakistani origin.
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A total of 4 patients were selected for isolation and amplifi-
cation of the HCV E2 sequence of 3a genotype. The tem-
plate cDNA used for PCR amplification was obtained after
the reverse transcription of RNA extracted from the serum
of HCV patients. PCR was optimized and run at specific
conditions of the primers to get a product of expected gene
size. Figure 1 shows the PCR amplify fraction of the gene
fragments i.e. 1151 bp of the E2 gene.
Cloning and confirmation of HCV 3a E2 in pCR2.1 vector
Gel purified PCR product of the HCV E2 gene was
cloned into pCR2.1 TA cloning vector. PCR amplifica-
tion was carried out for the confirmation of the HCV E2
gene cloning. Same PCR conditions were used for the
amplification of the gene from the plasmid (pCR2.1/
HCV E2 gene), the same size of PCR products was ob-
served when run on 1.2% agarose gel. The PCR positive
clones were used for further confirmation analysis by re-
striction digestion of the plasmid containing the HCV E2
(pCR2.1/HCV E2). Since pCR2.1 plasmid (3.9 KB)
con-tained 2 EcoRI sites, just outside the cloning site
in TA vector, restriction digestion with this enzyme
result in the linear plasmid of 3.9 KB and the PCR
fragment size of individual genes. Digested and un-
digested plasmids were run on 1% TAE agarose gel.
Figure 2 shows the digested product of 3900 KB size
for the plasmid and 1151 bp, fragments of HCV E2
when observed under the U.V light confirming the inser-
tion of the HCV E2 gene.
Structural description of the 3D model
The genetic diversity of the HCV largely impacts in the
treatment management as well as the development of
new HCV antiviral strategies. Sequence analysis of local
HCV 3a E2 gene obtained after sequencing from differ-
ent patients’ serum samples was performed using
protparam, DiANNA, I-TASSER, Procheck and ProsA
Z-Score. Physiochemical parameters of the HCV E2Table 2 Predicted disulfide bonds
Predicted bonds
46 - 170 RTARNCNESIK - GRWFGCTSMNS
69 - 126 FKLTGCPQRLS - CGPGYCFTPSP
76 - 208 QRLSSCKPITF - FCPTDCFRKHP
112 - 204 YAPRPCDTVKQ - GRELFCPTDCF
121 - 187 KQPTVCGPGYC - CGGPPCDIYGG
182 - 355 GFVKTCGGPPC - CHPRVCVALWL
220 - 300 ATYSRCGSGPW - LAILPCSFTPM
243 - 350 LWHYPCTVNFT - VFLLLCHPRVC
267 - 275 RFTAACNWTRG - TRGERCDIEDRprotein showed that it is 365 aa long sequence and had a
molecular weight of 41046.2 Daltons and theoretical iso-
electric point (PI) of 8.95. An isoelectric point above 7
indicates a positively charged protein. The instability
index (II) is computed to be 41.32. This classifies the
protein as unstable. The N-terminus of the sequence is
considered to be V (Val). The negative Grand average of
hydropathicity (GRAVY) of −0.170 indicates that the
protein is hydrophilic. Rich amounts of Glycine (G),
Leucine (L), Threonine (T) and Proline (P) were found
in the protein. Secondary structural features are shown
in Figure 3. Disulfide bonds predicted by DiANNA are
shown in the Table 2. Disulfide connectivity was pre-
dicted to be in between 1–8, 2–7, 3–12, 5–11, 6–10,
9–19, 13–17, 14–18, 15–16. Protein functions, inter-
actions and localizations can be understood by the
3D structure of proteins [24], therefore, 3D structure
of the HCV E2 protein was predicted using the
I-TASSER online server and the best predicted structure
with the maximum confidence score (C-Score −2.18)
was selected (Figure 4A). Quality and reliability of the
structure was checked using Z-score, and Ramachandram
plot. The Stereochemical quality of 3D structure was
checked by Ramachandran plot via analyzing residue-
by-residue geometry and overall structure geometry.
The result of the Ramachandran plot showed 73.1%
of residues in the favorable region (Figure 4B). Over-
all model quality can be checked by ProsA Z-score,
which is used to check whether the input structure is
within the range of scores typically found for native
proteins of similar size. The Z-score of the protein was
−0.6 (Figure 4C). The Ramachandran plot and Z-score
results confirmed the quality of the homology model of
the HCV E2 protein.Epitope prediction
The TMHMM online server showed that residues 1–340
presented outside region, residues 341–363 were within
the transmembrane and residues 364–365 were inside
the region of the protein. Vexijen v2. 0 showed an over-
all antigenic score of 0.4653.B-cell epitope prediction
B-cell epitopes are important for protection against virus
infection. B-cell epitopes were predicted using BCPred
having the criteria of length 9 and 75% specificity using
BCPred algorithm. 19 epitopes were predicted and all of
them were exposed outside of the membrane.
Antigenecity of epitopes was checked using Vexijen v2.0
and it was found that out of 19 epitopes 7 were non-
antigen thereby, resulting its exclusion (Table 3). Epi-
topes with antigenic properties can be important in
raising the desired immune responses.
Figure 4 3-D structure of the HCV E2 protein. A. Predicted 3 Dimensional structure of the HCV Envelope protein 2 using Homology Modelling.
B. Ramachandran plot showing residues in the most favorable region and disallowed regions. C. Z-score showing the quality of 3D structure.
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Table 3 B-cell epitopes with their antigenic score
Position Epitope BCPred score Antigenecity score Antigen/non-antigen
136 TTDPKGAST 0.999 0.6265 Antigen
278 EDRDRSEQH 0.999 −0.0020 Non-Antigen
191 GGGGRSTNG 0.996 0.4167 Antigen
4 ITGGTAARG 0.994 2.7513 Antigen
268 NWTRGERCD 0.919 0.7977 Antigen
92 ANITGPSDD 0.9 −0.3755 Non-Antigen
316 HQNIVDVQY 0.892 1.5115 Antigen
115 VKQPTVCGP 0.891 0.5372 Antigen
303 TPMPALSTG 0.854 0.5271 Antigen
223 GPWLTPQRM 0.843 0.8162 Antigen
126 CFTPSPVVV 0.836 1.0952 Antigen
169 GCTSMNSTG 0.821 0.3500 Non-Antigen
212 HPEATYSRC 0.777 −0.3926 Non-Antigen
31 INTNGSWHI 0.766 1.0793 Antigen
42 TARNCNESI 0.75 0.2912 Non-Antigen
82 FRQGWGPLT 0.747 1.5574 Antigen
180 KTCGGPPCD 0.725 −0.6164 Non-Antigen
104 CWHYAPRPC 0.725 0.8901 Antigen
65 KLTGCPQRL 0.723 −0.4238 Non-Antigen
Non-antigens are shown in bold text.
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Epijen online server predicted the T-cell epitopes on the
basis of the IC50 value. Epitopes that had minimum
IC50 value and exposed outside of the membrane were
checked for their antigenecity using Vexijen v2. 0
(Table 4). Epitopes at position 86, 132, 237, 307, 314,
and 335 were found to be the probable antigen and were
used for conservation analysis.
Conservation of epitopes
A total of 44 sequences of the HCV E2 of 1a and a total
of 50 sequences of 3a was retrieved from the NCBI pro-
tein database. The IEDB conservancy analysis tool was used
to check the conservancy of antigneically effective epitopes
(B-cell and T-cell). B-Cell epitope NWTRGERCD at
position 268, HQNIVDVQY at position 316 and CFTPS
PVVV at position 126 were found to be conserved. T-Cell
epitope RLWHYPCTV at position 237 for HLA: A*0201,
ALSTGLIHL at position 307 for HLA: A*0201, A*0202
and A*0203 and HLHQNIVDV at position 314 for HLA:
A*0203 were also found to be conserved. Conserved
B-Cell and T-Cell epitopes are shown in the Table 5.
Epitope HQNIVDVQY at position 316 had a max-
imum antigenic score (1.5115) ensuring maximum
bonding.
Discussion
Advancements in biotechnology and knowledge of im-
mune responses have opened new doors for vaccinedevelopment and implementation. Discovery of vaccine
using genetic information through in-silico approach ra-
ther than in-vitro study is called as reverse vaccinology
[33]. Reverse Vaccinology takes advantage of the gen-
ome sequence of the pathogen. This approach helps
in identifying all antigens of pathogens and also al-
lows the discovery of novel antigens [34]. Gene se-
quences of viral pathogens have been used to develop
synthetic peptides, used for vaccines against chronic
infections such as Hepatitis B, Hepatitis C and HIV.
Peptide based vaccines have shown efficacy in clinical
trials and this efficacy correlate with the induction of
the T cell-specific immunity. Bioinformatics resources,
store and organize immune reactivity and pathogen
data and availability of genomic sequences of patho-
gens can provide new information on cancer-specific
epitopes and increase our knowledge to design novel
peptide vaccines [35]. Many vaccines that were im-
possible to develop have now become a reality [34].
The most common HCV genotype in Pakistan is 3a
while 1a is common in Balochistan with a strong cor-
relation between chronic HCV infection (genotype 3a)
and HCC in Pakistan [2].
This study was designed to perform in-silico analysis
of the HCV E2 protein isolated in Pakistan. For this
purpose, different sequence and structure analysis tools
were used to explore the insights of the HCV E2 and
to compare the HCV E2 sequence of Pakistan with
other Pakistani E2 sequences. There is currently no
Table 4 T-cell epitopes on the basis of minimum IC50 value and antigenic score
Position Epitope Predicted IC50 value (nM) Allele Antigenic score Antigen/non-antigen
226 LTPQRMVDY 7.57 A*0101 0.3723 Non-Antigen
237 RLWHYPCTV 0.12 A*0201 0.4100 Antigen
346 FLLLCHPRV 0.17 A*0201 0.0731 Non-Antigen
324 YLYGVGSGM 0.24 A*0201 0.3163 Non-Antigen
307 ALSTGLIHL 0.43 A*0201 0.9005 Antigen
248 TLFKVRMFV 0.86 A*0202 −0.1899 Non-Antigen
307 ALSTGLIHL 2.25 A*0202 0.9005 Antigen
65 KLTGCPQRL 3.09 A*0202 −0.4238 Non-Antigen
237 RLWHYPCTV 3.46 A*0202 0.4100 Antigen
307 ALSTGLIHL 0.10 A*0203 0.9005 Antigen
65 KLTGCPQRL 0.17 A*0203 −0.4238 Non-Antigen
311 GLIHLHQNI 0.17 A*0203 0.2190 Non-Antigen
314 HLHQNIVDV 1.19 A*0203 0.5275 Antigen
312 LIHLHQNIV 3.80 A*0206 0.0960 Non-Antigen
248 TLFKVRMFV 7.45 A*0206 −0.1899 Non-Antigen
57 GLFYYHKFK 0.25 A*0301 −0.0505 Non-Antigen
93 NITGPSDDK 0.47 A*0301 0.0978 Non-Antigen
243 CTVNFTLFK 3.16 A*0301 0.1623 Non-Antigen
132 VVVGTTDPK 2.88 A*1101 1.8674 Antigen
172 SMNSTGFVK 3.30 A*1101 0.3124 Non-Antigen
305 MPALSTGLI 4.62 B*07 0.3991 Non-Antigen
355 CVALWLMLM 6.58 B*07 −0.0937 Non-Antigen
335 WAFKWEFVI 7.59 B*51 1.3516 Antigen
86 WGPLTDANI 8.69 B*51 0.8344 Antigen
Non-Antigens are shown in bold text.
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to further understand its mechanism of viral entry or
immune evasion [36]. We used a homology modeling
approach to predict the 3D structure of the HCV E2
protein of Pakistan. The predicted 3D structure will
provide more insight in understanding the structure
and function of the protein. Moreover, this structure
can be used for drug designing or understanding the
interactions between proteins. As a part of the present
study, we predicted conserved T-cell and B-cell epi-
topes that can be used as the target for vaccine devel-
opment against HCV genotype 3a and 1a. Among all





RLWHYPCTV T-Cell (A*0201, A*0202)
ALSTGLIHL T-Cell (A*0201, A*0202, A*0203)
HLHQNIVDV T-Cell (A*0203)to be antigenically effective and all these epitopes were
in the exo-membrane region of the protein. After con-
servation analysis it was found that only 3 epitopes were
conserved with other E2 sequences of genotype 3a and
1a. For T-cell epitope mapping, the Epijen online server
was used. A total of 25 epitopes with minimum IC50
value were selected and 9 were found to be antigenically
effective, but only 3 T-cell epitopes were found to be well
conserved in E2 sequences of genotype 3a and 1a.Conclusion
Multiple antigenic components of the virus can be a
important target to develop effective vaccines, thus
directing the immune system to protect the host from
the virus. In Pakistan, genotype 3a is the most prevalent
genotype followed by 3b and 1a. Keeping this in mind,
this study was conducted to perform sequence, struc-
ture, and conservation/variation analysis along with
homology modeling of the HCV E2 protein of Pakistani
origin. This study revealed B-cell and T-cell epitopes
that are conserved in 3a and 1a E2 protein of HCV. For
diagnosing HCV genotype 3a and 1a, these conserved
epitopes may be highly useful and may also help in
Idrees et al. Journal of Translational Medicine 2013, 11:105 Page 9 of 9
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3a and 1a genotypes.
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